ANNX Quote, Financials, Valuation and Earnings

Exelixis, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of 32.38%. Annexon, Inc.'s return on equity of -84.23% beat Exelixis, Inc.'s return on equity of 31.26%.

Annexon, Inc. has a consensus price target of $14.33, signalling upside risk potential of 205.62%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could grow by 3.9%. Given that Annexon, Inc. has higher upside potential than Exelixis, Inc., analysts believe Annexon, Inc. is more attractive than Exelixis, Inc..

Annexon, Inc. has a beta of 1.191, which suggesting that the stock is 19.091% more volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.171%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Annexon, Inc.'s net income of -$54.9M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 18.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 5.45x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of -162.11%. Annexon, Inc.'s return on equity of -84.23% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

Annexon, Inc. has a consensus price target of $14.33, signalling upside risk potential of 205.62%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 376.19%. Given that Marker Therapeutics, Inc. has higher upside potential than Annexon, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.191, which suggesting that the stock is 19.091% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.371, suggesting its more volatile than the S&P 500 by 37.092%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Annexon, Inc.'s net income of -$54.9M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 4.18x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spruce Biosciences has a net margin of -- compared to Annexon, Inc.'s net margin of -1440.37%. Annexon, Inc.'s return on equity of -84.23% beat Spruce Biosciences's return on equity of -58.1%.

Annexon, Inc. has a consensus price target of $14.33, signalling upside risk potential of 205.62%. On the other hand Spruce Biosciences has an analysts' consensus of $1.00 which suggests that it could grow by 640.74%. Given that Spruce Biosciences has higher upside potential than Annexon, Inc., analysts believe Spruce Biosciences is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.191, which suggesting that the stock is 19.091% more volatile than S&P 500. In comparison Spruce Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spruce Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Spruce Biosciences pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Spruce Biosciences quarterly revenues of $602K. Annexon, Inc.'s net income of -$54.9M is lower than Spruce Biosciences's net income of -$14M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Spruce Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 0.02x for Spruce Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of --. Annexon, Inc.'s return on equity of -84.23% beat Savara, Inc.'s return on equity of -78.83%.

Annexon, Inc. has a consensus price target of $14.33, signalling upside risk potential of 205.62%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 91.71%. Given that Annexon, Inc. has higher upside potential than Savara, Inc., analysts believe Annexon, Inc. is more attractive than Savara, Inc..

Annexon, Inc. has a beta of 1.191, which suggesting that the stock is 19.091% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.168%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Annexon, Inc.'s net income of -$54.9M is lower than Savara, Inc.'s net income of -$29.6M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.